Massachusetts, often considered a difficult place to do business, is becoming a popular choice for a key global sector: European life sciences companies.

Executives from the Continent’s pricey precincts are unfazed by Boston-area costs and the trans-Atlantic flights. And they see the Massachusetts biomedical cluster as a gateway to a US market that increasingly looks like a safe haven from Europe’s debt crisis.